<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04166032</url>
  </required_header>
  <id_info>
    <org_study_id>18-1385</org_study_id>
    <nct_id>NCT04166032</nct_id>
  </id_info>
  <brief_title>Validation Study for the Alertgy Non-invasive Continuous Glucose Monitor (ANICGM)</brief_title>
  <official_title>Validation Study for the Alertgy Non-invasive Continuous Glucose Monitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alertgy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes mellitus (DM) affects 30 million people in the United States. To achieve glucose&#xD;
      control, most patients are prescribed glucose meters by their physicians. Obtaining glucose&#xD;
      levels in this manner necessitates cleaning the fingers, attaching a lancet to a device (or&#xD;
      simply using a lancet if a device is not available), pricking the finger with a lancet,&#xD;
      placing a drop blood on a strip, and awaiting the readout that results after some chemical&#xD;
      reactions. Thereafter, the lancet has to be disposed of in a safe receptacle and the finger&#xD;
      has to be blotted to stop the blood from oozing.&#xD;
&#xD;
      The anxiety, pain, and tedious process have led researchers to develop other means of&#xD;
      checking glucose levels. There are now continuous glucose monitoring systems (CGMS) that&#xD;
      entail inserting a subcutaneous sensor that sends readings through a transmitter. These CGMs&#xD;
      may or may not need calibration with a fingerstick glucose reading, and the subcutaneous&#xD;
      sensor still has to be changed every 10 -14 days.&#xD;
&#xD;
      The Alertgy non-invasive continuous glucose monitor (ANICGM) is a device that does not entail&#xD;
      any subcutaneous insertion of a sensor. It is strapped on to the wrist, and glucose readings&#xD;
      are given based on subcutaneous signals. In 2001, a non-invasive device called Glucowatch&#xD;
      Biographer was introduced that also involved subcutaneous signals without needing a&#xD;
      subcutaneous insertion. However, for various reasons such as long calibration period and&#xD;
      reading inaccuracies, the product did not take off. The ANICGM is a promising device that&#xD;
      might overcome the limitations of existing and previous methods of non-invasive glucose&#xD;
      measurement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ANICGM uses a weak electromagnetic field generated by its wrist band sensor to look into&#xD;
      the body to produce a spectrum that provides a measurement of blood glucose present in the&#xD;
      wrist area of the body. The core sensing technology used is dielectric spectroscopy, and has&#xD;
      been shown capable of measuring blood glucose, non-invasively, in a laboratory environment.&#xD;
      The system uses proprietary and patented dielectric materials and signal processing to&#xD;
      enhance performance in both selectivity and sensitivity for blood glucose measurement.&#xD;
&#xD;
      Much like how a MRI uses a strong magnetic field and its interaction with the body to create&#xD;
      a picture of what is inside, the ANICGM uses a safe weak low frequency radiofrequency field&#xD;
      to take a picture of a person's chemical spectrum, some of it specific only to blood glucose.&#xD;
&#xD;
      The device sends and receives back signals from the wrist area that are used to generate a&#xD;
      dielectric spectrum once every 6 seconds. The POC BG using the Accuchek Inform II will be&#xD;
      used to provide calibration values for the ANICGM every 5 minutes in mg/dL, during the&#xD;
      calibration process. The POC BG levels will be entered into the Alertgy laptop and a&#xD;
      proprietary calibration program will be used to analyze the spectral data collected and will&#xD;
      generate a calibration algorithm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 6, 2019</start_date>
  <completion_date type="Actual">May 30, 2020</completion_date>
  <primary_completion_date type="Actual">February 4, 2020</primary_completion_date>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Absolute Relative Difference (MARD) of Glucose Values Between the ANICGM and FDA-approved Glucose Monitoring Device</measure>
    <time_frame>2 time points taken over 2 separate days respectively, over a span of up to 14 days</time_frame>
    <description>Hypothesis is that ANICGM device will perform similarly as other blood glucose monitoring devices Mean absolute relative difference (MARD) is computed by taking the arithmetic mean of the absolute relative differences between the ANICGM system measures and the reference standard FS BG, which serves as the denominator of the calculation. The MARD is expressed as a percentage, and a lower MARD signifies better concordance between the two measurements.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>ANICGM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>non-invasive continuous glucose monitoring device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alertgy non-invasive continuous glucose monitoring device (ANICGM)</intervention_name>
    <description>Alertgy non-invasive continuous glucose monitoring device (ANICGM)</description>
    <arm_group_label>ANICGM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes on diet or on pharmacologic treatment for diabetes&#xD;
&#xD;
          -  Hemoglobin A1c between 7.5 - 10.0%&#xD;
&#xD;
          -  Age 18 - 75 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients taking prandial insulin&#xD;
&#xD;
          -  Fasting blood glucose by fingerstick of &lt; 70 mg/dL or &gt;250 mg/dL&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  End stage renal disease&#xD;
&#xD;
          -  Decompensated or acute heart failure&#xD;
&#xD;
          -  Medications that may cause false readings with glucose meters: acetaminophen, ascorbic&#xD;
             acid, dopamine, maltodextrin, mannitol&#xD;
&#xD;
          -  Conditions that limit the ANICGM such as lesions on the forearms&#xD;
&#xD;
          -  Other conditions that the investigator deems will affect the conduct of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <results_first_submitted>May 26, 2021</results_first_submitted>
  <results_first_submitted_qc>October 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 9, 2021</results_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>M. Cecilia Lansang, MD</investigator_full_name>
    <investigator_title>Professor of Medicine, Endocrinology Staff Physician</investigator_title>
  </responsible_party>
  <keyword>glucose monitor</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 14, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT04166032/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ANICGM</title>
          <description>non-invasive continuous glucose monitoring device&#xD;
Alertgy non-invasive continuous glucose monitoring device (ANICGM): Alertgy non-invasive continuous glucose monitoring device (ANICGM)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ANICGM</title>
          <description>non-invasive continuous glucose monitoring device&#xD;
Alertgy non-invasive continuous glucose monitoring device (ANICGM): Alertgy non-invasive continuous glucose monitoring device (ANICGM)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.0" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Absolute Relative Difference (MARD) of Glucose Values Between the ANICGM and FDA-approved Glucose Monitoring Device</title>
        <description>Hypothesis is that ANICGM device will perform similarly as other blood glucose monitoring devices Mean absolute relative difference (MARD) is computed by taking the arithmetic mean of the absolute relative differences between the ANICGM system measures and the reference standard FS BG, which serves as the denominator of the calculation. The MARD is expressed as a percentage, and a lower MARD signifies better concordance between the two measurements.</description>
        <time_frame>2 time points taken over 2 separate days respectively, over a span of up to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ANICGM</title>
            <description>non-invasive continuous glucose monitoring device&#xD;
Alertgy non-invasive continuous glucose monitoring device (ANICGM): Alertgy non-invasive continuous glucose monitoring device (ANICGM)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Relative Difference (MARD) of Glucose Values Between the ANICGM and FDA-approved Glucose Monitoring Device</title>
          <description>Hypothesis is that ANICGM device will perform similarly as other blood glucose monitoring devices Mean absolute relative difference (MARD) is computed by taking the arithmetic mean of the absolute relative differences between the ANICGM system measures and the reference standard FS BG, which serves as the denominator of the calculation. The MARD is expressed as a percentage, and a lower MARD signifies better concordance between the two measurements.</description>
          <units>percentage difference</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="12.8" upper_limit="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="12.3" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.210</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>No adverse events reported</desc>
      <group_list>
        <group group_id="E1">
          <title>ANICGM</title>
          <description>non-invasive continuous glucose monitoring device&#xD;
Alertgy non-invasive continuous glucose monitoring device (ANICGM): Alertgy non-invasive continuous glucose monitoring device (ANICGM)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Company will review any publication submission within 30 days of estimated due date. If CCF does not hear from company we are to assume we are free to publish. If company identities patentable information they can request for CCF to withhold submission for 90 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kimberly Jenkins, Research Administrator</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216-445-4791</phone>
      <email>jenkink@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

